Published in Fam Cancer on December 01, 2012
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int (2013) 1.02
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet (2015) 0.94
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract (2016) 0.83
New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics (2015) 0.81
Common low-penetrance risk variants associated with breast cancer in Polish women. BMC Cancer (2013) 0.81
Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J Appl Genet (2014) 0.80
The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine. Hered Cancer Clin Pract (2015) 0.77
PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. BMC Med Genomics (2017) 0.75
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population. Hered Cancer Clin Pract (2016) 0.75
Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw. Contemp Oncol (Pozn) (2016) 0.75
Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine. Fam Cancer (2017) 0.75
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer. Fam Cancer (2013) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol (2007) 3.26
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Basal-like breast cancer and the BRCA1 phenotype. Oncogene (2006) 2.62
Inherited susceptibility to common cancers. N Engl J Med (2008) 2.54
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer (2004) 1.96
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol (2010) 1.18
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer (2002) 1.14
Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet (2011) 1.12
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine. Expert Rev Mol Diagn (2009) 1.01
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases. Fam Cancer (2012) 0.91
Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas (2004) 0.88
Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol (2002) 0.86
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives. Eur J Gynaecol Oncol (2004) 0.79
Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland. Fam Cancer (2010) 0.77
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. Onkologie (2009) 0.75
hnRNP K: one protein multiple processes. Bioessays (2004) 2.96
Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One (2010) 2.32
Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene (2003) 1.83
Liver-to-thoracic volume ratio: use at MR imaging to predict postnatal survival in fetuses with isolated congenital diaphragmatic hernia with or without prenatal tracheal occlusion. Eur Radiol (2012) 1.39
A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet (2010) 1.34
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Breast cancer leptomeningeal metastasis--the role of multimodality treatment. J Neurooncol (2007) 1.25
Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer (2006) 1.13
Landscape of the hnRNP K protein-protein interactome. Proteomics (2006) 1.12
Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet (2011) 1.12
Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer (2004) 1.07
Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol (2013) 1.02
Cooperative binding of the hnRNP K three KH domains to mRNA targets. FEBS Lett (2004) 1.01
Pooled sample-based GWAS: a cost-effective alternative for identifying colorectal and prostate cancer risk variants in the Polish population. PLoS One (2012) 1.00
Quantitative detection for low levels of Helicobacter pylori infection in experimentally infected mice by real-time PCR. J Microbiol Methods (2003) 0.97
The fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53. Cell Cycle (2008) 0.96
Evaluation of the effects of mammography screening program on cancer progression and implemented treatment in patients with breast cancer. Pol Przegl Chir (2013) 0.95
Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol (2006) 0.95
An integrated LC-ESI-MS platform for quantitation of serum peptide ladders. Application for colon carcinoma study. Proteomics Clin Appl (2009) 0.94
Characterization of hnRNP K protein-RNA interactions. J Mol Biol (2004) 0.93
Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med Genet (2008) 0.92
High Resolution Melting analysis as a rapid and efficient method of screening for small mutations in the STK11 gene in patients with Peutz-Jeghers syndrome. BMC Med Genet (2013) 0.92
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases. Fam Cancer (2012) 0.91
Comprehensive analysis of the palindromic motif TCTCGCGAGA: a regulatory element of the HNRNPK promoter. DNA Res (2010) 0.90
Preliminary studies on DNA retardation by MutS applied to the detection of point mutations in clinical samples. Mutat Res (2005) 0.88
Increased expression of ribosomal protein S2 in liver tumors, posthepactomized livers, and proliferating hepatocytes in vitro. Acta Biochim Pol (2002) 0.86
A common cis-element in promoters of protein synthesis and cell cycle genes. Acta Biochim Pol (2007) 0.86
The hppA gene of Helicobacter pylori encodes the class C acid phosphatase precursor. FEBS Lett (2002) 0.85
Helicobacter pylori VacA cytotoxin interacts with fibronectin and alters HeLa cell adhesion and cytoskeletal organization in vitro. FEMS Immunol Med Microbiol (2005) 0.84
Helicobacter pylori protein oxidation influences the colonization process. Int J Med Microbiol (2006) 0.84
Detection of cytomegalovirus in human placental cells by polymerase chain reaction. APMIS (2006) 0.84
[West Nile Virus infection in perinatology]. Ginekol Pol (2007) 0.84
[Seroprevalence of cytomegalovirus infection in the population of Polish pregnant women]. Ginekol Pol (2012) 0.83
Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol (2007) 0.83
[Evaluation of antenatal quality of life of hospitalized women with the use of Mother-Generated Index--pilot study]. Ginekol Pol (2010) 0.83
Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. Mitochondrion (2003) 0.82
[SARS-CoV infection and pregnancy]. Ginekol Pol (2008) 0.82
Up-regulation of human PNPase mRNA by beta-interferon has no effect on protein level in melanoma cell lines. Acta Biochim Pol (2006) 0.82
Mitochondrial-related proteomic changes during obesity and fasting in mice are greater in the liver than skeletal muscles. Funct Integr Genomics (2013) 0.82
[Diagnosis and treatment of carcinoid meningitis: a challenge to the neurologist and oncologist]. Neurol Neurochir Pol (2003) 0.82
Massive fetal intracranial teratoma with hydrocephalus detected at 33 weeks of gestation. Neuro Endocrinol Lett (2010) 0.81
Common low-penetrance risk variants associated with breast cancer in Polish women. BMC Cancer (2013) 0.81
Association between gynecomastia and aromatase (CYP19) polymorphisms. Eur J Endocrinol (2008) 0.81
Pre-analytical-related variability influencing serum peptide profiles demonstrated in a mass spectrometry-based search for colorectal and prostate cancer biomarkers. Acta Biochim Pol (2013) 0.81
Increased mitochondrial gene expression during L6 cell myogenesis is accelerated by insulin. Int J Biochem Cell Biol (2005) 0.81
Casein kinases phosphorylate multiple residues spanning the entire hnRNP K length. Biochim Biophys Acta (2006) 0.81
Adipokines and genetic factors in overweight or obese but metabolically healthy Polish women. Neuro Endocrinol Lett (2010) 0.81
Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus. J Mol Med (Berl) (2007) 0.81
Tip-alpha (hp0596 gene product) is a highly immunogenic Helicobacter pylori protein involved in colonization of mouse gastric mucosa. Curr Microbiol (2008) 0.80
Alterations in TLRs as new molecular markers of congenital infections with Human cytomegalovirus? Pathog Dis (2013) 0.80
The diverse involvement of heterogeneous nuclear ribonucleoprotein K in mitochondrial response to insulin. FEBS Lett (2006) 0.80
The binding activity of yeast RNAs to yeast Hek2p and mammalian hnRNP K proteins, determined using the three-hybrid system. Cell Mol Biol Lett (2005) 0.79
Gene expression alterations induced by low molecular weight heparin during bowel anastomosis healing in rats. Acta Biochim Pol (2011) 0.79
Barrett's esophagus associates with a variant of IL23R gene. Acta Biochim Pol (2008) 0.79
Identification of a late onset Alzheimer's disease candidate risk variant at 9q21.33 in Polish patients. J Alzheimers Dis (2012) 0.79
Stomach position versus liver-to-thoracic volume ratio in left-sided congenital diaphragmatic hernia. J Matern Fetal Neonatal Med (2014) 0.79
Mannan-binding lectin-2 (MBL2) gene polymorphisms in prenatal and perinatal cytomegalovirus infections. Mol Immunol (2011) 0.79
First Polish Cowden syndrome patient with confirmed PTEN gene mutation. Arch Med Sci (2010) 0.79
Multivariate analysis of risk factors for development of duodenal ulcer in Helicobacter pylori-infected patients. Digestion (2003) 0.78
Lack of evidence for increased level of circulating urothelial cells in the peripheral blood after transurethral resection of bladder tumors. Int Urol Nephrol (2011) 0.78
Halogenated imidazole derivatives block RNA polymerase II elongation along mitogen inducible genes. BMC Mol Biol (2010) 0.78
Expression of genes encoding mitochondrial proteins can distinguish nonalcoholic steatosis from steatohepatitis. Acta Biochim Pol (2007) 0.78
Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. J Cell Mol Med (2014) 0.77
Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland. Fam Cancer (2010) 0.77
Mitochondria-associated satellite I RNA binds to hnRNP K protein. Acta Biochim Pol (2006) 0.77
Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med (Berl) (2011) 0.77
[Knowledge of toxoplasmosis among pregnant women, midwifes, medical students and obstetricians]. Med Pr (2010) 0.77
[Detection of congenital toxoplasmosis in utero with a polymerase chain reaction on amniotic fluid]. Wiad Parazytol (2002) 0.77
Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer. BMC Cancer (2008) 0.77
Inferring serum proteolytic activity from LC-MS/MS data. BMC Bioinformatics (2012) 0.76
CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patients. Med Oncol (2014) 0.76
Two-stage model-based clustering for liquid chromatography mass spectrometry data analysis. Stat Appl Genet Mol Biol (2009) 0.76
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. Onkologie (2009) 0.75
DNA repair mechanisms and Toxoplasma gondii infection. Arch Microbiol (2013) 0.75
DNA repair mechanisms and human cytomegalovirus (HCMV) infection. Folia Microbiol (Praha) (2014) 0.75
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer. Fam Cancer (2013) 0.75
[Prevalence of uterine malformations and their impact on fertility]. Ginekol Pol (2012) 0.75
Clinical challenges in the management of a prenatally diagnosed cloacal malformation. Congenit Anom (Kyoto) (2011) 0.75
[Determinants of smoking cessation during pregnancy]. Przegl Lek (2010) 0.75